Department of Laboratory Medicine Malmö, Lund University, 20502 Malmö, Sweden.
Vaccine. 2011 Feb 1;29(6):1129-34. doi: 10.1016/j.vaccine.2010.11.070. Epub 2010 Dec 4.
Kaposi's sarcoma-associated herpes virus (KSHV) encodes its own inhibitor of the complement system, designated KSHV complement control protein (KCP). Previously, we detected anti-KCP antibodies in a small group of 22 patients suffering from Kaposi's sarcoma (KS) and KSHV-related lymphoproliferative diseases (Vaccine, 25:8102-9). Anti-KCP antibodies were more prevalent in individuals suffering from KSHV-related lymphomas than KS and also in those with high titer of antibodies against lytic KSHV antigens. Herein we analyze anti-KCP antibodies in 175 individuals originating from three different groups from northern Sweden or Italy, which included patients suffering from classical or HIV-associated KS, Multicentric Castleman's Disease, KSHV-associated solid lymphoma, pleural effusion lymphoma and healthy individuals with detectable KSHV immune response. Our current study confirmed previous observations concerning antibody prevalence but we also analyzed correlations between anti-KCP antibodies and classical KS evolution, clinical stage and viral load in body fluids. Furthermore, we show that patient's anti-KCP antibodies are able to decrease the ability of KCP to inhibit complement. This fact combined with results of statistical analysis suggests that KCP inactivation by specific antibodies may influence progression of classical KS.
卡波济肉瘤相关疱疹病毒（KSHV）编码其自身的补体系统抑制剂，称为 KSHV 补体控制蛋白（KCP）。之前，我们在一小群 22 名患有卡波济肉瘤（KS）和 KSHV 相关淋巴增生性疾病的患者中检测到抗 KCP 抗体（疫苗，25:8102-9）。与 KS 相比，抗 KCP 抗体在患有 KSHV 相关淋巴瘤的个体中更为普遍，并且在那些针对裂解 KSHV 抗原的抗体滴度高的个体中更为普遍。在此，我们分析了来自瑞典北部或意大利的三个不同群体的 175 名个体的抗 KCP 抗体，这些个体包括患有经典或 HIV 相关 KS、多中心 Castleman 病、KSHV 相关实体瘤、胸腔积液淋巴瘤和具有可检测到的 KSHV 免疫反应的健康个体。我们的当前研究证实了之前关于抗体流行率的观察结果，但我们还分析了抗 KCP 抗体与经典 KS 演变、临床阶段和体液中病毒载量之间的相关性。此外，我们表明患者的抗 KCP 抗体能够降低 KCP 抑制补体的能力。这一事实加上统计分析的结果表明，特异性抗体对 KCP 的失活可能会影响经典 KS 的进展。
